Viral Hepatitis Conference to Take Place February 27-28, 2006 in Boston, MA (Hepatitis C Infection)

Viral Hepatitis Conference to Take Place February 27-28, 2006 in Boston, MA
RedNova - Jan 05 8:20 AM
BOSTON, Jan. 5 /PRNewswire/ -- Chronic hepatitis C (HCV) and B (HBV) are the most common causes of chronic viral hepatitis in the United States, posing serious risks for long-term medical complications, especially if left untreated.Save to My Web

Human Genome Sciences Announces Decision to Spin Off CoGenesys Division as an Independent Company
[Press Release] PR Newswire via Yahoo! Finance - Dec 13 1:05 PM
Human Genome Sciences, Inc. today announced that it has decided to spin off its CoGenesys division as an independent company that will focus on the early development of selected gene-based product opportunities and the monetization of certain Human Genome Sciences intellectual property and technology assets.Save to My Web

Keryx Biopharmaceuticals, Inc. Announces Appointment of Senior Pharmaceutical Executive to Board of Directors
[Press Release] PR Newswire via Yahoo! Finance - Jan 04 5:29 AM
Keryx Biopharmaceuticals, Inc. today announced the appointment of Jonathan Spicehandler, M.D., to the Company's Board of Directors.Save to My Web

Cubist Pharmaceuticals Reports Results From Phase 2 Study Hepex-B(TM), Which Was Licensed From XTLbio
FinanzNachrichten - Dec 22 12:02 AM
REHOVOT, Israel, December 22 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. ( Nachrichten ) ("XTLbio") announces that Cubist Pharmaceuticals, ( Nachrichten ) Inc. today provided data from a recently concluded Phase 2 study of HepeX-B(TM) which was licensed to Cubist by XTLbio in 2004. In the Phase 2 study, HepeX-B was studied as maintenance therapy to prevent reinfection with hepatitis B Save to My Web